27 September 2019 - Pivotal Phase III evidence shows significant improvements with Erbitux in combination with FOLFOX versus FOLFOX alone in response rate, disease progression and survival.

Merck, a leading science and technology company, today announced that Erbitux (cetuximab) has been granted approval by the National Medical Products Administration of China for the first-line treatment for patients with RAS wild-type metastatic colorectal cancer in combination with FOLFOX or FOLFIRI, or in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy. 

The pivotal Phase III evidence from the TAILOR study, on which the approval was based, shows significant benefit in overall response rate, progression-free survival and overall survival for patients treated with Erbitux in combination with FOLFOX, compared to FOLFOX alone, in the first-line setting for this challenging type of cancer.

Read Merck press release